LIBTAYO study results
LIBTAYO helped shrink tumors in some clinical trial patients.
In 1 clinical trial of 193 patients with CSCC that had spread or could not be cured by surgery or radiation treated with LIBTAYO*:
91 out of 193 patients (47%)
saw an improvement in their advanced CSCC with LIBTAYO
- In 84 out of 91 patients (92%) who responded to LIBTAYO, the response lasted 6 months or longer
- In 70 out of 91 patients (77%) who responded to LIBTAYO, the response lasted 12 months or longer
In the same clinical trial, in a subgroup of 56 patients with CSCC that had spread who took LIBTAYO at the recommended dose†:
-
26 out of 56 patients (46%) saw an improvement in their advanced CSCC
- 15 out of 56 patients (27%) saw tumors shrink (partial response)
- 11 out of 56 patients (20%) saw tumors disappear completely (complete response)
- In 25 out of 26 patients (96%) who responded to LIBTAYO, the response lasted 6 months or longer
In a different clinical trial of 26 patients with CSCC that had spread or could not be cured by surgery or radiation:
-
13 out of 26 patients (50%) saw tumors shrink (all partial responses)
- In 11 out of 13 patients (85%) who responded to LIBTAYO, the response lasted 6 months or longer
In these trials, responses lasted between 1 month and more than 4 years (54.6 months).
- *137 out of 193 patients in the trial were dosed by body weight; 56 out of 193 were given the recommended dose.
- †LIBTAYO 350 mg over a 30-minute infusion every 3 weeks.
LIBTAYO may not work for everyone.